CN108697666A - 用于治疗卵巢癌的组合疗法 - Google Patents
用于治疗卵巢癌的组合疗法 Download PDFInfo
- Publication number
- CN108697666A CN108697666A CN201780013983.4A CN201780013983A CN108697666A CN 108697666 A CN108697666 A CN 108697666A CN 201780013983 A CN201780013983 A CN 201780013983A CN 108697666 A CN108697666 A CN 108697666A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- repair
- dna damage
- ovarian cancer
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301225P | 2016-02-29 | 2016-02-29 | |
| US62/301,225 | 2016-02-29 | ||
| PCT/US2017/019843 WO2017151554A1 (en) | 2016-02-29 | 2017-02-28 | Combination therapy for treatment of ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108697666A true CN108697666A (zh) | 2018-10-23 |
Family
ID=59744380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780013983.4A Pending CN108697666A (zh) | 2016-02-29 | 2017-02-28 | 用于治疗卵巢癌的组合疗法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11154538B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3423048A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019508429A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697666A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017227534A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014680A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261195B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018010223A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017151554A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113462784A (zh) * | 2021-08-31 | 2021-10-01 | 迈杰转化医学研究(苏州)有限公司 | 一种构建用于同源重组修复缺陷检测的靶标集合的方法 |
| CN116024162A (zh) * | 2023-02-27 | 2023-04-28 | 山东大学 | Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用 |
| CN117860753A (zh) * | 2023-11-30 | 2024-04-12 | 华中科技大学 | 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| KR20200106053A (ko) * | 2017-12-29 | 2020-09-10 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 억제제를 사용한 암 치료 방법 |
| JP2021510702A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 相乗的がん治療 |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| JPWO2023157891A1 (cg-RX-API-DMAC7.html) | 2022-02-16 | 2023-08-24 | ||
| WO2024111564A1 (ja) * | 2022-11-21 | 2024-05-30 | 富士フイルム株式会社 | トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬 |
| TW202502354A (zh) * | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140255348A1 (en) * | 2011-11-02 | 2014-09-11 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP2714038A1 (en) * | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
| EP2714033A1 (en) * | 2011-05-26 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| JP6114075B2 (ja) * | 2013-03-07 | 2017-04-12 | 三菱航空機株式会社 | 航空機の警報システム、及び、航空機 |
| US20160120848A1 (en) * | 2013-05-21 | 2016-05-05 | Synta Pharmaceuticals Corp. | Specific cancer treatment regimes with ganetespib |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
-
2017
- 2017-02-28 US US16/080,752 patent/US11154538B2/en not_active Expired - Fee Related
- 2017-02-28 CA CA3014680A patent/CA3014680A1/en active Pending
- 2017-02-28 JP JP2018545198A patent/JP2019508429A/ja active Pending
- 2017-02-28 WO PCT/US2017/019843 patent/WO2017151554A1/en not_active Ceased
- 2017-02-28 EP EP17760573.0A patent/EP3423048A4/en not_active Withdrawn
- 2017-02-28 AU AU2017227534A patent/AU2017227534A1/en not_active Abandoned
- 2017-02-28 CN CN201780013983.4A patent/CN108697666A/zh active Pending
- 2017-02-28 MX MX2018010223A patent/MX2018010223A/es unknown
-
2018
- 2018-08-16 IL IL261195A patent/IL261195B/en unknown
-
2022
- 2022-03-29 JP JP2022053212A patent/JP2022079569A/ja not_active Withdrawn
-
2023
- 2023-02-03 AU AU2023200554A patent/AU2023200554A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019509A patent/JP2024054312A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140255348A1 (en) * | 2011-11-02 | 2014-09-11 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| TIMMS ET AL.: "《Association of BRCA1/2 Detects with Genomic Scores Predictive of DNA Damage Repair Deficiency Among Breast Cancer subtypes》", 《BREAST CANCER RESEARCH》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113462784A (zh) * | 2021-08-31 | 2021-10-01 | 迈杰转化医学研究(苏州)有限公司 | 一种构建用于同源重组修复缺陷检测的靶标集合的方法 |
| CN113462784B (zh) * | 2021-08-31 | 2021-12-10 | 迈杰转化医学研究(苏州)有限公司 | 一种构建用于同源重组修复缺陷检测的靶标集合的方法 |
| CN116024162A (zh) * | 2023-02-27 | 2023-04-28 | 山东大学 | Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用 |
| CN117860753A (zh) * | 2023-11-30 | 2024-04-12 | 华中科技大学 | 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024054312A (ja) | 2024-04-16 |
| MX2018010223A (es) | 2018-11-09 |
| US11154538B2 (en) | 2021-10-26 |
| CA3014680A1 (en) | 2017-09-08 |
| WO2017151554A1 (en) | 2017-09-08 |
| US20190060285A1 (en) | 2019-02-28 |
| AU2023200554A1 (en) | 2023-03-02 |
| IL261195B (en) | 2022-06-01 |
| JP2019508429A (ja) | 2019-03-28 |
| EP3423048A1 (en) | 2019-01-09 |
| AU2017227534A1 (en) | 2018-08-30 |
| JP2022079569A (ja) | 2022-05-26 |
| IL261195A (en) | 2018-10-31 |
| EP3423048A4 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024054312A (ja) | 卵巣がんの処置のための併用療法 | |
| Begg et al. | Strategies to improve radiotherapy with targeted drugs | |
| JP7083760B2 (ja) | 卵巣癌の治療方法 | |
| Stoyanov et al. | On the concepts and history of glioblastoma multiforme—morphology, genetics and epigenetics | |
| JP6742391B2 (ja) | 併用療法 | |
| Michels et al. | Predictive biomarkers for cancer therapy with PARP inhibitors | |
| Kang et al. | Advances in lung cancer driver genes associated with brain metastasis | |
| CA2990703A1 (en) | Biomarkers for nanoparticle compositions | |
| Anwer et al. | Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma | |
| Tufail | DNA repair pathways in breast cancer: from mechanisms to clinical applications | |
| CN121772925A (zh) | 作为用wee1抑制剂治疗癌症的预测性生物标志物的同源重组修复缺陷(hrd) | |
| BR112021014657A2 (pt) | Métodos para tratar câncer de próstata com base em subtipos moleculares | |
| Shi et al. | Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma | |
| US20180057888A1 (en) | Kub5/hera as a determinant of sensitivity to dna damage | |
| Figel et al. | Cell-cycle regulation | |
| US20170342503A1 (en) | Xrn2 as a determinant of sensitivity to dna damage | |
| US10106853B2 (en) | CUL4B as predictive biomarker for cancer treatment | |
| Chatterjee et al. | Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer | |
| TW202116316A (zh) | 治療卵巢、輸卵管及腹膜癌之方法 | |
| Yoon et al. | Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer | |
| Shakeel et al. | Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy | |
| CA3036568C (en) | Methods for treating ovarian cancer | |
| Xiang et al. | KIF15 (Kinesin-12): molecular biology, physiological functions, and roles in disease | |
| Merlini | PARP1 and immune checkpoint inhibition after chemotherapy induction in leiomyosarcoma: a model to unleash immunoresponse | |
| WO2025162446A1 (zh) | 一种egfr抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
| RJ01 | Rejection of invention patent application after publication |